Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?

被引：13

作者：

Recher, Mike ^{[1
]}

Sahrbacher, Ulrike ^{[1
]}

Bremer, Juliane ^{[2
]}

Arndt, Boerge ^{[1
]}

Steiner, Urs ^{[1
]}

Fontana, Adriano ^{[1
]}

机构：

[1] Univ Zurich Hosp, Clin Immunol, Dept Internal Med, CH-8044 Zurich, Switzerland

[2] Univ Zurich Hosp, Inst Neuropathol, Dept Pathol, CH-8091 Zurich, Switzerland

来源：

RHEUMATOLOGY INTERNATIONAL | 2012年 / 32卷 / 02期

关键词：

IBM; IVIG; Myositis; Inclusion body myositis; Low-dose IVIG; IDIOPATHIC THROMBOCYTOPENIC PURPURA; ANTIINFLAMMATORY ACTIVITY; INFLAMMATORY MYOPATHIES; GAMMA-GLOBULIN; DOUBLE-BLIND; IVIG; DERMATOMYOSITIS; FC; POLYMYOSITIS; RECEPTOR;

D O I：

10.1007/s00296-009-1290-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inclusion body myositis (IBM), the most common inflammatory myopathy in the elderly, is often resistant to various forms of therapy. Placebo-controlled treatment trials with high dose intravenous immunoglobulins (IVIG) have shown disease amelioration in some but not all patients. Here, we present the informative case of a 70-year-old woman with diagnosed inclusion body myositis that showed progressive muscle weakness without treatment and following immuno-suppressive treatment with corticosteroids and azathioprine. A trial with low-dose intravenous immunoglobulins was started at that time. The patient responded rapidly to low dose IVIG treatment with amelioration of muscle strength and normalization of CK serum activities. Our results demonstrate that IBM patients may respond to low-dose IVIG treatment which has important clinical and economic consequences.

引用

页码：469 / 472

页数：4

共 18 条

[1] Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc [J].

Anthony, Robert M. ;

Nimmerjahn, Falk ;

Ashline, David J. ;

Reinhold, Vernon N. ;

Paulson, James C. ;

Ravetch, Jeffrey V. .

SCIENCE, 2008, 320 (5874) :373-376

[2] Identification of a receptor required for the anti-inflammatory activity of IVIG [J].

Anthony, Robert M. ;

Wermeling, Fredrik ;

Karlsson, Mikael C. I. ;

Ravetch, Jeffrey V. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (50) :19571-19578

[3]

BUSSEL JB, 1983, BLOOD, V62, P480

[4] POLYMYOSITIS, DERMATOMYOSITIS, AND INCLUSION-BODY MYOSITIS [J].

DALAKAS, MC .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1487-1498

[5] The role of high-dose immune globulin intravenous in the treatment of dermatomyositis [J].

Dalakas, MC .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (04) :550-556

[6] Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study [J].

Dalakas, MC ;

Sonies, B ;

Dambrosia, J ;

Sekul, E ;

Cupler, E ;

Sivakumar, K .

NEUROLOGY, 1997, 48 (03) :712-716

[7] A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies [J].

Dastmalchi, M. ;

Grundtman, C. ;

Alexanderson, H. ;

Mavragani, C. P. ;

Einarsdottir, H. ;

Helmers, S. Barbasso ;

Elvin, K. ;

Crow, M. K. ;

Nennesmo, I. ;

Lundberg, I. E. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1670-1677

[8] The current status of treatment for inclusion-body myositis [J].

Griggs, RC .

NEUROLOGY, 2006, 66 :S30-S32

[9] Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies [J].

Helmers, Sevim Barbasso ;

Dastmalchi, Maryam ;

Alexanderson, Helene ;

Nennesmo, Inger ;

Esbjornsson, Mona ;

Lindvall, Bjorn ;

Lundberg, Ingrid E. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (10) :1276-1283

[10]

IMBACH P, 1981, LANCET, V1, P1228

← 1 2 →